Personalized cancer chemotherapy: efficacy and safety based on pharmacokinetics and pharmacogenetics

Research Project

Project/Area Number	25460202
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Medical pharmacy
Research Institution	National Cancer Center Japan
Principal Investigator	Hamada Akinobu 国立研究開発法人国立がん研究センター, その他部局等, 分野長 (00322313)
Co-Investigator(Kenkyū-buntansha)	TAMURA Kenji 国立研究開発法人国立がん研究センター, 中央病院, 科長 (60340783) FUJIWARA Yutaka 国立研究開発法人国立がん研究センター, 中央病院, 医長 (70464261)
Project Period (FY)	2013-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000) Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000) Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000) Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords	薬物動態 / 個別化医療 / ABCB1 / クリゾチニブ / エリブリン / 薬理遺伝学 / 臨床薬理 / 薬理遺伝学的解析 / LC/MS/MS
Outline of Final Research Achievements	In 78 non-small cell lung cancer (ALK fusion gene-positive) patients treated with crizotinib, the trough plasma concentration of crizotinib did not correlate the development of liver dysfunction and QT prolongation. On the other hand, the association of ABCB1 1236TT-2677TT-3435TT genotype with crizotinib pharamcokinetics was observed. In 29 inoperable or recurrent breast cancer patient treated with eribulin the results of interim analysis suggest that the development of over grade 3 myelosuppression may be associated with the plasma concentration of eribulin after 24 hour administration.